Opinion|Videos|January 8, 2026
Real-World Treatment Patterns in R/R LBCL: Insights from Flatiron Data Pre & Post 2L CAR T Approval
Fact checked by: Justin Mancini
Panelists discuss real-world treatment patterns for relapsed/refractory LBCL using the Flatiron Health electronic health record database. The conversation examines shifts in second- and third-line therapy use following CAR T approval, including declining reliance on salvage chemotherapy and transplant.
Advertisement
Episodes in this series
Panelists discuss real-world treatment patterns for relapsed/refractory LBCL using the Flatiron Health electronic health record database. The conversation examines shifts in second- and third-line therapy use following CAR T approval, including declining reliance on salvage chemotherapy and transplant.
Advertisement
Related to this article
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
3
Building out a Radiopharmaceuticals Program in Oncology Care
4
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression
5